Gastritis Clinical Trial
Official title:
A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Based on Accurate Susceptibility Testing of Clarithromycin
As the resistant rate of the Helicobacter pylori to some common antibiotics was rising,the eradication rate of the Helicobacter pylori with the standard triple therapy failed to exceed 70% in China,and had to drop out of the first-line treatment recommendations. However, with the increase of treatment time, patients burden, adverse reactions of antibiotics or proton pump inhibitor (PPI) will also increase. Resistance to clarithromycin is the major cause of the failure to eradicate Helicobacter pylori. But, in terms of population, there are still more than 70% of the patients with clarithromycin sensitive. Under the guidance with susceptibility test,7-day standard triple therapy could be used. In this study, investigators will select the patients with infection of H. pylori and with clarithromycin sensitive. Eradication of Helicobacter pylori with triple therapy based on accurate susceptibility testing of clarithromycin will be studied. The treatment time will be assigned into 7 days,10 days and 14 days groups. Then, investigators will perform a sequencing for failed treatment patients in groups, such as drug resistance gene mutation, phenotype and genotype. Finally, investigators will compare the differences between the patients with triple therapy and traditional quadruple therapy.The incidence of adverse effects in the eradicate treatment will reduce at least 10% and avoid patients' unnecessary economic losses at least 400RMB per person.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04289519 -
Endoscopic Findings of Gastritis in Children
|
||
Recruiting |
NCT02353039 -
Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis
|
Phase 2 | |
Recruiting |
NCT05545397 -
Sedation Level on Machine Learning With Electroencephalogram in Painless Gastroenteroscopy Patients
|
||
Not yet recruiting |
NCT05510388 -
HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
|
N/A | |
Completed |
NCT02724280 -
Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy
|
N/A | |
Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
Completed |
NCT02385045 -
i-Scan for the Detection of Helicobacter Pylori
|
N/A | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT04672018 -
Efficacy and Safety of Houtou Jianweiling Tablet in the Treatment of Chronic Non-Atrophic Gastritis
|
Phase 2 | |
Not yet recruiting |
NCT05072938 -
Phase IV Clinical Trial to Compare the Efficacy and Safety of Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis
|
Phase 4 | |
Completed |
NCT02597517 -
New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy
|
N/A | |
Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT01576289 -
Analysis of Biopsies From the Upper Gastrointestinal Tract
|
N/A | |
Active, not recruiting |
NCT03509831 -
[KJ-INT-002] BE Study
|
Phase 1 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Suspended |
NCT04306939 -
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
|
||
Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT02393430 -
Clinical Effect of Rebamipide on Chronic Gastritis
|
Phase 4 | |
Completed |
NCT00579410 -
Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule
|
N/A | |
Completed |
NCT00267475 -
Data Bank for Eosinophilic Disorders
|
N/A |